ReviewTherapeutic advances in medical oncology2026
Neoadjuvant therapy versus upfront surgery followed by adjuvant chemotherapy in resectable or borderline resectable PDAC: a systematic review and meta-analysis of RCTs.
Review in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adjuvant chemotherapy remains the standard of care following resection of pancreatic ductal adenocarcinoma (PDAC). However, despite advances with modern multi-agent regimens, most patients relapse, underscoring the need for alternative strategies. Neoadjuvant therapy offers several theoretical advantages, but evidence directly comparing it with upfront surgery remains limited. Objectives: To compare efficacy and postoperative safety outcomes between neoadjuvant therapy and upfront surgery among patients with resectable or borderline resectable PDAC. Design: We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) evaluating outcomes in patients with resectable or borderline resectable PDAC treated with either neoadjuvant chemotherapy and/or chemoradiotherapy or upfront surgery followed by adjuvant chemotherapy. Data sources and methods: Outcomes of interest included overall survival, disease-free survival (DFS), R0 resection rate, and postoperative complication rates. Literature searches were performed in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials, supplemented by clinical trial registries, conference abstracts, and gray literature. Study selection and data extraction were conducted independently by two authors. Sensitivity and subgroup analyses were performed to assess sources of heterogeneity. Results: We included 13 RCTs, with one study excluded from the primary analysis due to high risk of bias. Neoadjuvant treatment did not confer a statistically significant benefit in overall survival (hazard ratio (HR) = 0.79; 95% confidence interval (95% CI), 0.58-1.10). However, neoadjuvant treatment was associated with improved DFS (HR = 0.79; 95% CI, 0.66-0.93) and a higher R0 resection rate (OR = 1.51; 95% CI, 1.04-2.19). There was no significant difference in the rate of major postoperative morbidity after resection (OR = 1.27; 95% CI, 0.61 - 2.62). Subgroup analyses revealed larger treatment effects in overall survival, DFS, and R0 resection rate in favor of neoadjuvant treatment among patients with borderline resectable PDAC. Conclusion: The survival advantage of neoadjuvant treatment in resectable or borderline resectable PDAC remains uncertain. Nonetheless, preoperative therapy improves DFS and R0 resection rates, with patients with borderline resectable disease deriving the greatest benefit. These findings should be interpreted with caution, given the limitations of the available evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.